Breast Cancer Diagnostics Articles & Analysis
31 news found
Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been selected as the winners of the Best KTP project by Innovate UK. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, exceeding the expectations ...
October marks a month dedicated to a cause close to the core of everything which we do at Cirdan: Breast Cancer Awareness. This month will see a surge in activism surrounding breast cancer awareness and a push for finding a cure from around the globe. The fight to treat and cure breast cancer continues constantly, and we pride ourselves in taking part in the fight to save lives. Breast cancer ...
Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been shortlisted for Innovate UK’s esteemed Best Knowledge Transfer Partnership Award. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, ...
Prelude Corporation (PreludeDx, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). ...
Prelude Corporation (PreludeDx, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that its study in 926 DCIS patients demonstrating the clinical utility of DCISionRT? ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that it has closed a $20 million funding round led by Evidity Health Capital and joined by existing and new investors including BlueStone Venture Partners. ...
(Seno Medical), a Texas-based medical imaging company developing breakthrough breast cancer diagnostic technology, announced an educational partnership supporting Worldwide Breast Cancer’s “Know Your Lemons” campaign starting with the Netherlands, which has one of the highest ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data comparing DCISionRT? ...
Following the success of the world's leading AI Breast Care system, Transpara®, now in use across the US and in 30 countries worldwide, ScreenPoint Medical, the company that developed Transpara, has appointed Mark Koeniguer as its new CEO to lead the next phase of growth and accelerate the company's international expansion. Koeniguer, who has extensive experience leading and growing ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced the publication of SweDCIS randomized clinical trial data in the Special Issue: Updates on Breast Cancer edition of Cancers. ...
Kheiron Medical Technologies, an award-winning applied science company based in the United Kingdom, has launched RSViP™, a new artificial intelligence-enabled tool that helps breast screening programs optimize scheduling for women who are at risk for potentially developing breast cancer. ...
” ScreenPoint’s AI algorithm, Transpara, assists breast radiologists in improving their accuracy for both 2D and 3D mammography, which can help detect cancers earlier and reduce overall reading time. ...
ByAidoc
In Nigeria, breast cancer is becoming the major health problem, representing nearly 25% of all new cancer diagnoses in the country. The parties at the signing ceremony have agreed to co-develop Breast Cancer Centers of Excellence which will deliver comprehensive, compassionate breast ...
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced the advancement of its regulatory strategy in China with the submission of an amendment to the registration certificate for the IceSense3® system, which was granted ...
Atlanta, GA: A month into Koning’s Republic fundraising campaign, the company has already passed a quarter of a million dollars of investments from 740 investors. “We’re proud of the progress we’ve made on the campaign so far and we’re confident that this positive trajectory will continue”, says Koning’s US CEO, Lutao Ning. “It goes to show how ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that its study in 926 patients demonstrating the clinical utility of DCISionRT and its Residual Risk Subtype (RRt) was selected for a scientific session oral presentation at the American Society of ...
” The breast cancer investigations conducted so far at the University of Leeds using the 4D Q-plasia OncoReader Breast platform have focused on identifying the presence of breast cancer and determining its subtype, grade, HER2 and hormone receptor status from H&E stained whole slide biopsy images only. ...
(Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions. ...
An artificial intelligence (AI)-based breast ultrasound software from Koios Medical, Inc. proven to significantly enhance the accuracy and consistency of lesion assessment for physicians across a wide range of experience levels, per a study recently published in the American Journal of Roentgenology, is now being used to diagnose breast cancer earlier for patients with appointments cancelled due ...